Paper Details

  1. Home
  2. Paper Details

Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients.

Author: EgidiM F, GaberA O, GaberL W, LoA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Sirolimus, a mammalian target of rapamycin inhibitor, was evaluated for its efficacy and safety in kidney transplant recipients. Posttransplant use of sirolimus was associated with low incidence of rejection. Hematologic and lipid side effects were manageable, as was an observed increase in wound-healing problems and lymphocele formation.
Paper Details　
Original Abstract of the Article :
Sirolimus is the first of a group of mammalian target of rapamycin inhibitors to be introduced for clinical use in the United States. At the University of Tennessee in Memphis, we have evolved strategies for the use of sirolimus in kidney transplant recipients; which utilize the drug as a primary im...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0041-1345(03)00238-0

データ提供：米国国立医学図書館（NLM）

Sirolimus in Renal Transplant Recipients: A Promising Immunosuppressant

Organ transplantation, a life-saving procedure, is like a fragile oasis in the desert of disease. This research explores the use of sirolimus, a novel immunosuppressant, in high-risk renal transplant recipients. The study reveals the potential of sirolimus in preserving renal function and reducing the incidence of rejection. The authors highlight the importance of careful monitoring and adjustments to sirolimus protocols to optimize its benefits and minimize potential side effects.

The Promise of Sirolimus

Sirolimus holds promise as a primary immunosuppressant in renal transplant recipients, particularly in high-risk patients. The study suggests that sirolimus can effectively prevent rejection and preserve renal function, potentially offering a valuable alternative to traditional immunosuppressive agents.

Health Implications and Lifestyle Applications

Individuals undergoing renal transplantation should discuss the potential benefits and risks of sirolimus with their healthcare providers. Open communication and careful monitoring are essential for optimizing treatment outcomes and minimizing potential side effects.

Dr.Camel's Conclusion

Sirolimus shows promise as a valuable tool in the field of renal transplantation. However, careful monitoring and individualized treatment strategies are essential to maximize its benefits and minimize potential risks. Further research is needed to refine sirolimus protocols and ensure its long-term effectiveness and safety.

Date :
  1. Date Completed 2003-12-17
  2. Date Revised 2019-07-13
Further Info :

Pubmed ID

12742477

DOI: Digital Object Identifier

10.1016/s0041-1345(03)00238-0

Related Literature

Article Analysis
・Effects of sirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.